Skip to main content
Premium Trial:

Request an Annual Quote

Ronald Andrews

OncoCyte has appointed Ronald Andrews as its CEO, effective July 1. In addition to serving as a board member at OncoCyte, Andrews has over 30 years of experience in the clinical and molecular diagnostics field. OncoCyte's current CEO, William Annett, will remain with the company in an advisory role.

Prior to joining the firm, Andrews was the founder and principal of the Bethesda Group. Before Bethesda, he served as Thermo Fisher Scientific's genetic science division president, where he oversaw the integration of Life Technologies' genetic platform. He also served as president of Life Tech's Medical Science Venture. Before joining Life Tech, Andrews acted as CEO at Clarient (formerly ChromaVision Medical Systems), which was sold to GE Healthcare in 2010. He subsequently served as GE Molecular Diagnostics' CEO until 2011. Andrews also held various senior executive roles at Roche Diagnostics from 2000 to 2004. Andrews served as VP of marketing at Immucor from 1995 to 2000. Prior to Immucor, Andrews spent about 10 years in management positions at Abbott Diagnostics.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.